annual sales of diovan ratingFull Year 2017 Product Sales. Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also a global leader in eye care and generics products. Read more about the 2017 sales of our top 20 pharmaceutical products in the table below. PERFORMANCE Net sales rise 16% (+12% in constant currencies) to USD 58.6 billion. Operating income down 5% (+1% cc) to USD 11.0 billion, following a net exceptional charge of USD 1.9 billion. Core operating income increases 14% (+16% cc) to USD 15.9 billion. Net income of USD 9.2 billion declines 7% (-2% cc) in line with operating income. Novartis said its best-selling drug, the high-blood-pressure treatment Diovan, was well on track to soon achieve annual sales of billion. View detailed sales data for Diovan, updated quarterly. Subscribe for email updates.
5-5 stars based on 39 reviews
6Dividend payment for 2009: Proposal to 2010 Annual General Meeting NET SALES costco pharmacy lipitor price OPERATING INCOME, NET INCOME, ... 8 NOVARTIS GROUP ANNUAL REPORT 2009 It generated .4B sales in 2012 alone, up 17% from 2011. Gilenya is the first once-daily oral therapy drug approved for relapsing remitting forms of multiple sclerosis. In 2012, it achieved blockbuster status with class="site-content" role="main">
.2B in annual sales, up from 0M a year before. Diovan was Novartis' number-one product till generics hit the market in spring 2015. From .5 billion in 2013 sales-- class="site-content" role="main">
.7 billion the U.S.--Diovan has dropped to class="site-content" role="main">
.3 billion, total. Novartis is expecting a .2 billion hit from generics this year, including Gleevec copies. The longtime consumer-products executive is betting Novartis can maintain a third of the .1 billion in annual sales of Diovan, a hypertension ... Net sales from co ntinuing operations rise 9% (+5% in local curre ncies) to USD 41.5 billion. Operating income advances 32% thanks to business expansion and beneﬁts of the Forward productivity initiative launched in 2007 to improve speed, ﬂexibility and productivity.Operatingmarginimprovesto21.6%ofnetsalesfrom17.8%in2007. Valsartan is mainly used for treatment of high blood pressure, congestive heart failure, and to increase the chances of living longer after a heart attack. It is an angiotensin II receptor antagonist, that is selective for the type I angiotensin receptor.